Rep. Arrington and Bipartisan Group Introduce ETHIC Act to Limit Drug Patent Lawsuits
The ETHIC Act was recently introduced in the House and is currently being reviewed by the House Committee on the Judiciary. This is the first step in the legislative process, and no further actions are scheduled at this time. The bill is considered active as it begins its journey through the committee system.
The bill has strong support from both parties and addresses high drug costs, but it will face heavy opposition from the powerful pharmaceutical lobby.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
Generic drug manufacturers, many of which are smaller companies compared to major pharmaceutical firms, would face fewer legal barriers when trying to bring competing products to market. The bill limits how many patents a brand-name company can use in a single lawsuit, reducing the cost and complexity of defending against infringement claims.
“A person who brings an action described in subparagraph (A) asserting a patent against a party may not bring any additional actions described in that subparagraph asserting a patent in the same Patent Group against that party.”
Referred to the House Committee on the Judiciary.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
ETHIC Act
Analysis generated by AI. Always verify with official sources.
